Skip to main content

Day: August 15, 2024

Xylo Technologies: ParaZero Received Order from a Leading Tier-One Defense Company for 50 Drone Safety Systems

TEL AVIV, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) — Xylo Technologies Ltd. (Nasdaq: XYLO) (“Xylo” or the “Company”), a technology-based company engaged in advanced innovative technologies, announced today that ParaZero Technologies Ltd. (Nasdaq: PRZO) ( “ParaZero”), an aerospace company focused on drone safety systems for defense and commercial drones and urban air mobility aircraft (18.68% owned by Xylo), initiated a partnership with a leading Tier 1 defense OEM company to adapt and integrate its advanced drone safety system for operational military and medical mission use. ParaZero received an initial order as part of a wider collaboration that aims to enhance the efficiency and safety of medical field mission’s deliveries, particularly in critical and remote areas. In the initial phase, ParaZero will provide 50 systems to the...

Continue reading

MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder’s equity and gross revenues. During the six months ending June 30, 2024, MangoRx’s shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial portion of this increase is attributed to the Company’s recent acquisition of the comprehensive global patent portfolio surrounding respiratory...

Continue reading

Protect Pharmaceutical Corp. (PRTT) Announces New CEO and New Director; Moves to Finalize the Karinca Logistics Merger

ANKARA, Turkey, Aug. 15, 2024 (GLOBE NEWSWIRE) — Protect Pharmaceutical Corp. (OTC: PRTT) (“Company”) announces the appointment of a new CEO, restructuring of the Board of Directors, and looks to finalize the merger agreement with Karinca Logistics – www.karincalogistics.com. The Company appointed Ozgur Ozcan as CEO and Director and George Athanasiadis as Director. Further, the Company accepted the resignations of Ali Yildiz as CEO and Tatiana Aleinikov as VP of Operations. The Board restructuring and the appointment of the new CEO are the first steps to ensure a smooth transition with the merger, which should be finalized in the next few days in Turkey. Ozgur Ozcan, PRTT’s CEO, stated, “This is an exciting time for the Company. I look forward to working towards our goals within the Company. I will...

Continue reading

Blüm Holdings Inc. Reports Second Quarter 2024 Financial Results, Showcasing Strategic Progress and Net Income of $23.4 Million

SANTA ANA, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Blüm Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm Holdings,” “we” or “us”), a cannabis company with subsidiaries operating throughout California, announced its financial results for the second quarter ended June 30, 2024. These results not only reflect our strong financial performance but also underscore the effectiveness of our ongoing strategic restructuring, debt reduction, and operational streamlining. Second Quarter 2024 HighlightsTransformative Sale of Blüm Santa Ana: In June 2024, we completed the sale of our controlling interest in People’s First Choice, LLC (“PFC”), which owns and operates the Blüm Santa Ana dispensary, to Haven Nectar LLC. This sale, a pivotal move in our restructuring strategy, provided $24.8 million in total consideration, including...

Continue reading

Montana Technologies Announces Memorandum of Understanding with TenX Investment to Deploy AirJoule® for Water Security and Sustainability in the United Arab Emirates

Montana Technologies and TenX signed a Memorandum of Understanding to explore options for deploying AirJoule® units to enhance energy efficiency and water security in the United Arab Emirates.Clockwise from top right: Ramdas Rao, President, International at Montana Technologies; Pat Eilers, Executive Chairman of Montana Technologies; Husain Al Awadhi, Managing Director at TenX; and Abdulrahman Al-Suwaidi, Managing Director at TenX.RONAN, Mont., Aug. 15, 2024 (GLOBE NEWSWIRE) — Montana Technologies Corporation (NASDAQ: AIRJ) (“Montana Technologies” or the “Company”), the developer of the transformational AirJoule® technology for atmospheric water generation, is pleased to announce the signing of a Memorandum of Understanding (“MOU”) with TenX Investment in Energy Enterprises & Management Co. LLC (“TenX”) to address...

Continue reading

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th. H.C. Wainwright 26th Annual Global Investment Conference: September 9th – 11th  Title: Lumos Pharma Corporate Presentation (On-Demand)  Date/Time: September 9th at 7:00AM EDT  Webcast Link: Register here  1×1 Meetings: Monday-Tuesday, September 9th-10th     The presentation webcast can be downloaded at 7:00AM EDT on September 9th and will be available for 90 days thereafter....

Continue reading

Aligos Therapeutics Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begin trading on the Nasdaq Capital Market under the same symbol (ALGS) on a split-adjusted basis at the market open on August 19, 2024 with the new CUSIP number 01626L 204. At the effective time, all outstanding stock options, warrants, and equity incentive plans will be proportionally affected. Every 25 shares of issued and outstanding shares...

Continue reading

Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference

Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept Rutherford, NJ, Aug. 15, 2024 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology innovator focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced new findings from a recent market research study evaluating the acceptance of its new Continuous Blood Glucose Monitor (CBGM) concept among people with insulin-requiring diabetes. The poster was presented at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference held Aug. 9-12, 2024, in New Orleans. The study, conducted with a diverse group of participants, revealed that over 50% of respondents are open...

Continue reading

Capital Power announces successful completion of consent solicitation process for its 7.95% Fixed-to-Fixed Rate Subordinated Notes, Series 1

EDMONTON, Alberta, Aug. 15, 2024 (GLOBE NEWSWIRE) — Capital Power Corporation (“Capital Power”, the “Company”, “we”, “us” or “our”) (TSX: CPX) announced today the completion of a previously announced solicitation of consents (the “Consent Solicitation”) from holders (“Holders”) of its C$350M 7.95% Fixed-to-Fixed Rate Subordinated Notes, Series 1, due September 9, 2082 (the “Series 1 Notes”). Based on the report of the tabulation agent for the Consent Solicitation, the Consent Solicitation received strong support and was approved by Holders, significantly exceeding the required threshold of at least 66 2/3% of the aggregate outstanding principal amount of the Series 1 Notes. As a result, the extraordinary resolution authorizing certain proposed amendments to the indenture governing the Series 1 Notes has been approved. The proposed...

Continue reading

NEVADA CANYON EXERCISES AN AMENDED OLINGHOUSE ROYALTY OPTION TO PURCHASE AGREEMENT

Reno, Nevada, Aug. 15, 2024 (GLOBE NEWSWIRE) — Nevada Canyon Gold Corp. (OTC Markets: NGLD) (The “Company” or “Nevada Canyon”) is pleased to announce through its wholly-owned subsidiary, Nevada Canyon, LLC, that it has amended and exercised its Option to Purchase Agreement (the “Agreement”) with Target Minerals, Inc (“Target”), a private Nevada company, and acquired one-hundred percent (100%) interest of Target’s one percent (1%) production royalty on the Olinghouse Project, located in the Olinghouse Mining District, Washoe County, Nevada.The Olinghouse Project is located approximately 30 miles east of Reno, Nevada. The property was operated by Alta Gold in the late 1990’s and Alta completed a feasibility study in 1997. The Olinghouse Project hosts an historic geologic resource (Alta Gold Feasibility Study 1997) based on over...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.